Cryoport, Inc. (NASDAQ:CYRX) CFO Sells $10,435.11 in Stock

Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich sold 1,659 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $10,435.11. Following the sale, the chief financial officer now owns 191,419 shares in the company, valued at $1,204,025.51. This represents a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Robert Stefanovich also recently made the following trade(s):

• On Monday, March 10th, Robert Stefanovich sold 1,256 shares of Cryoport stock. The stock was sold at an average price of $4.88, for a total value of $6,129.28.

Cryoport Stock Performance

CYRX stock opened at $5.84 on Thursday. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $20.11. The firm has a market cap of $291.47 million, a price-to-earnings ratio of -1.73 and a beta of 1.67. The business’s fifty day simple moving average is $6.92 and its two-hundred day simple moving average is $7.42. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The company had revenue of $59.53 million for the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the previous year, the business earned ($0.29) EPS. Analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CYRX shares. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Wednesday, March 5th. Guggenheim began coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Trading of Cryoport

A number of large investors have recently modified their holdings of CYRX. Point72 Asia Singapore Pte. Ltd. raised its position in Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC purchased a new position in shares of Cryoport during the fourth quarter valued at $51,000. Avanza Fonder AB bought a new stake in shares of Cryoport in the fourth quarter valued at about $64,000. Quarry LP purchased a new stake in Cryoport in the fourth quarter worth about $69,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Cryoport during the 3rd quarter worth about $82,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.